RecruitingRelapsed or Refractory Multiple Myeloma (RRMM)

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Eligible age

18+ yrs

Accepts

All genders

Locations

16 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

You may qualify if…

✓ Participants must have relapsed or refractory multiple myeloma (RRMM).
✓ Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody and have prior exposure to lenalidomide.
✓ Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria.
✓ Participants must have measurable disease during screening.
✓ Participants must have adequate organ function.
✓ Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.

You may not qualify if…

✕ Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM).
✕ Participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease.
✕ Participants must not need urgent treatment due to rapidly progressing MM.
✕ Other protocol-defined Inclusion/Exclusion criteria apply.